Search Site

BP announces $7bn gas project

The project aims to unlock 3 trillion cu ft of gas resources in Indonesia.

Lulu Retail Q3 profit $35m

For the nine-month period, net profit increased by 73.3%.

Talabat IPO offer price range announced

The subscription will close on 27 Nov for UAE retail investors.

Salik 9M net profit $223m

The company's third-quarter profit increased by 8.8 percent.

Avia to buy 40 Boeing aircraft

The transaction for the purchase of 737 MAX 8 jets valued at $4.9bn.

UAE children aged 3-17 to receive Chinese Sinopharm vaccine

    • The Gulf state, which has among the world’s highest immunization rates, was already providing the Pfizer-BioNTech vaccine for children aged 12-15

    • The UAE government took to twitter to make the announcement

    The United Arab Emirates has decided to inoculate children between the ages of 3 and 17 with Chinese Covid-19 vaccine Sinopharm. Although the Chinese vaccines have been criticized for their low efficacy, the UAE was still going ahead to vaccinate the younger children with the Sinopharm vaccine.

    The UAE government took to twitter to make the announcement. It cited the health ministry as saying the decision comes after clinical trials and extensive evaluations, without providing any details. Authorities said in June the trial would monitor the immune response of 900 children.

    The Gulf state, which has among the world’s highest immunization rates, was already providing the Pfizer-BioNTech vaccine for children aged 12-15.

    The health ministry said on Sunday that 78.95 percent of the UAE population of roughly 9 million had received one vaccine dose while 70.57 percent had been fully vaccinated.

    The UAE, the region’s tourism and trade hub, registered 1,519 new coronavirus infections on Sunday to take its total to 682,377 cases and 1,951 deaths. It does not provide a breakdown for each of its seven emirates.

    It led Phase III clinical trials of the vaccine produced by China’s state-owned drugmaker Sinopharm and has started manufacturing it under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42.